119 related articles for article (PubMed ID: 16051943)
1. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab.
Ellis LM; Curley SA; Grothey A
J Clin Oncol; 2005 Aug; 23(22):4853-5. PubMed ID: 16051943
[No Abstract] [Full Text] [Related]
2. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab.
Yoo PS; Lopez-Soler RI; Longo WE; Cha CH
Clin Colorectal Cancer; 2006 Sep; 6(3):202-7. PubMed ID: 17026789
[TBL] [Abstract][Full Text] [Related]
3. Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study.
Tamandl D; Gruenberger B; Klinger M; Herberger B; Kaczirek K; Fleischmann E; Gruenberger T
Ann Surg; 2010 Jul; 252(1):124-30. PubMed ID: 20562613
[TBL] [Abstract][Full Text] [Related]
4. Perioperative risks of bevacizumab and other biologic agents for hepatectomy: theoretical or evidence based?
Bilchik AJ; Hecht JR
J Clin Oncol; 2008 Apr; 26(11):1786-8. PubMed ID: 18398144
[No Abstract] [Full Text] [Related]
5. [The safety of perioperative bevacizumab use].
Mariani P
J Chir (Paris); 2010 Jan; 147 Suppl 1():S12-7. PubMed ID: 20172200
[TBL] [Abstract][Full Text] [Related]
6. In search of the black sheep: is it bevacizumab or extended chemotherapy?
Vauthey JN; Zorzi D
Ann Surg Oncol; 2009 Jun; 16(6):1463-4. PubMed ID: 19357926
[No Abstract] [Full Text] [Related]
7. Treatment of metastatic colorectal cancer with monoclonal antibody to vascular endothelial growth factor: does the metastatic site make the difference?
Graziano F; Cascinu S
J Clin Oncol; 2003 Sep; 21(18):3542-3; author reply 3543. PubMed ID: 12972535
[No Abstract] [Full Text] [Related]
8. [Two radically resected colorectal carcinoma cases with unresectable liver metastasis after adjuvant chemotherapy with bevacizumab].
Sugiyama M; Kakeji Y; Kubo N; Nakanoko T; Fujinaka Y; Ando K; Masuda T; Yagi K; Yoshinaga K; Saeki H; Endo K; Emi Y; Morita M; Maehara Y
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2169-71. PubMed ID: 20037359
[TBL] [Abstract][Full Text] [Related]
9. Management of colorectal liver metastases after complete response to neoadjuvant chemotherapy. A case of computertomography-guided wire marking of the liver tumor.
Kornprat P; Schöllnast H; Cerwenka H; Werkgartner G; Bernhardt G; Mischinger HJ
Int J Colorectal Dis; 2009 Jan; 24(1):125-6. PubMed ID: 18682963
[No Abstract] [Full Text] [Related]
10. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
Klinger M; Eipeldauer S; Hacker S; Herberger B; Tamandl D; Dorfmeister M; Koelblinger C; Gruenberger B; Gruenberger T
Eur J Surg Oncol; 2009 May; 35(5):515-20. PubMed ID: 19200687
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab and postoperative complications after hepatic surgery for colorectal metastases.
Petrelli NJ
J Clin Oncol; 2009 Apr; 27(11):1917; author reply 1918. PubMed ID: 19255304
[No Abstract] [Full Text] [Related]
12. Challenges in everyday surgical practice: synchronous bilobar hepatic colorectal metastases--newer multimodality approach.
Lygidakis NJ; Bhagat AD; Vrachnos P; Grigorakos L
Hepatogastroenterology; 2007 Jun; 54(76):1020-4. PubMed ID: 17629030
[TBL] [Abstract][Full Text] [Related]
13. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases.
Kesmodel SB; Ellis LM; Lin E; Chang GJ; Abdalla EK; Kopetz S; Vauthey JN; Rodriguez-Bigas MA; Curley SA; Feig BW
J Clin Oncol; 2008 Nov; 26(32):5254-60. PubMed ID: 18854565
[TBL] [Abstract][Full Text] [Related]
14. Sclerosing cholangitis in the era of target chemotherapy: a possible anti-VEGF effect.
Delis S; Triantopoulou C; Bakoyiannis A; Tassopoulos N; Athanasiou K; Dervenis C
Dig Liver Dis; 2009 Jan; 41(1):72-7. PubMed ID: 18294938
[TBL] [Abstract][Full Text] [Related]
15. Incidental reduction in the size of liver hemangioma following use of VEGF inhibitor bevacizumab.
Mahajan D; Miller C; Hirose K; McCullough A; Yerian L
J Hepatol; 2008 Nov; 49(5):867-70. PubMed ID: 18814928
[TBL] [Abstract][Full Text] [Related]
16. First- and second-line therapy of metastatic colorectal cancer.
Terstriep S; Grothey A
Expert Rev Anticancer Ther; 2006 Jun; 6(6):921-30. PubMed ID: 16761936
[TBL] [Abstract][Full Text] [Related]
17. Delayed bile leak with avastin after liver resection for metastatic colorectal cancer.
Lordan JT; Wilkins M; Karanjia ND
Hepatogastroenterology; 2011; 58(110-111):1769-70. PubMed ID: 22086700
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of hepatic metastasis in colorectal cancer.
Rossi H
J Surg Oncol; 2005 Dec; 92(4):276-7. PubMed ID: 16299795
[No Abstract] [Full Text] [Related]
19. Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels.
Brostjan C; Gebhardt K; Gruenberger B; Steinrueck V; Zommer H; Freudenthaler H; Roka S; Gruenberger T
Clin Cancer Res; 2008 Apr; 14(7):2065-74. PubMed ID: 18381946
[TBL] [Abstract][Full Text] [Related]
20. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study.
D'Angelica M; Kornprat P; Gonen M; Chung KY; Jarnagin WR; DeMatteo RP; Fong Y; Kemeny N; Blumgart LH; Saltz LB
Ann Surg Oncol; 2007 Feb; 14(2):759-65. PubMed ID: 17103075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
